Prophylactic ondansetron in prevention of postoperative nausea and vomiting following pediatric strabismus surgery: a

S Sadhasivam1, D Shende, R Madan

  • 1Department of Anesthesiology and Dr. Rajendra Prasad Center for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi.

Anesthesiology
|February 7, 2001
PubMed

Insights

A 75 microg/kg dose of ondansetron effectively prevents postoperative nausea and vomiting (PONV) in children undergoing strabismus repair. This dosage is as effective as higher doses, improving outcomes and parental satisfaction.

Area of Science:

  • Anesthesiology
  • Pediatric Surgery
  • Pharmacology

Background:

  • Postoperative nausea and vomiting (PONV) is a common complication in pediatric patients.
  • Strabismus repair surgery in children presents a specific risk for PONV.
  • Evaluating prophylactic antiemetic strategies is crucial for improving pediatric surgical outcomes.

Purpose of the Study:

  • To assess the antiemetic effectiveness of prophylactic ondansetron in pediatric patients undergoing strabismus repair.
  • To determine the optimal dose-response relationship for ondansetron in preventing PONV.
  • To evaluate the clinical usefulness and impact on patient outcomes of ondansetron prophylaxis.

Main Methods:

  • A randomized controlled trial involving 180 pediatric patients (2-12 years) undergoing strabismus repair.
  • Patients received placebo or intravenous ondansetron at doses of 25, 50, 75, 100, or 150 microg/kg.
  • PONV incidence, duration of postanesthesia care unit stay, and parental satisfaction were recorded over 24 hours.

Main Results:

  • Ondansetron significantly reduced PONV incidence at doses of 75, 100, and 150 microg/kg compared to placebo.
  • Shorter postanesthesia care unit stays and improved parental satisfaction were observed with 75, 100, and 150 microg/kg ondansetron.
  • The 75 microg/kg dose demonstrated equivalent efficacy and benefits to the 150 microg/kg dose.

Conclusions:

  • Prophylactic ondansetron at 75 microg/kg is an effective and clinically useful dose for preventing PONV in pediatric strabismus surgery.
  • This dose provides comparable benefits to higher doses, optimizing antiemetic therapy.
  • Routine use of 75 microg/kg ondansetron can improve perioperative outcomes in pediatric patients.
Abstract

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...